First-generation H1 antihistamines, introduced from the 1940s onward, are characterized by ready passage across the blood-brain barrier (BBB), significant muscarinic receptor antagonism, and broad adverse effect profiles that limit their use in many clinical contexts. Despite these limitations, several agents in this class retain important clinical roles where their CNS activity is therapeutically exploited rather than tolerated as a side effect.
The defining pharmacological feature of first-generation H1 antihistamines is lipophilicity sufficient to cross the BBB by passive diffusion. The BBB excludes charged and polar molecules while permitting passage of lipid-soluble compounds; first-generation agents satisfy this criterion because their chemical structures lack the polar substituents that restrict CNS entry in later agents. Once in the CNS, these drugs bind H1 receptors on tuberomammillary nucleus (TMN) neurons and suppress histaminergic arousal signals, producing sedation that ranges from mild drowsiness to profound somnolence depending on the agent and dose. This CNS penetration also underlies several therapeutic applications: the vestibular suppression used for motion sickness prophylaxis, the sedation exploited for short-term insomnia management, and the antiemetic effect mediated through central histamine and muscarinic receptor blockade in the chemoreceptor trigger zone (CTZ).1
All first-generation H1 antihistamines exhibit meaningful antagonism at muscarinic acetylcholine (ACh) receptors (M1 through M3 subtypes), an off-target activity that produces the anticholinergic adverse effect syndrome: dry mouth, urinary retention, constipation, blurred vision (cycloplegia), tachycardia, and in susceptible individuals delirium and confusion. Anticholinergic burden is quantified clinically by cumulative anticholinergic scoring systems and is a recognized contributor to cognitive impairment in the elderly, even at doses that appear well-tolerated in younger patients. Diphenhydramine carries among the highest anticholinergic burdens of any over-the-counter (OTC) medication, and its widespread use as a sleep aid in geriatric populations is a patient safety concern repeatedly flagged in American Geriatrics Society Beers Criteria recommendations. Promethazine has additional antidopaminergic activity (D2 receptor antagonism) that contributes to its antiemetic efficacy but also to extrapyramidal adverse effects and, in pediatric patients, life-threatening respiratory depression that prompted a black box warning for use in children under two years of age.2
Diphenhydramine is the prototypical first-generation H1 antihistamine and the benchmark against which others in the class are compared. Its pharmacokinetic (PK) profile includes oral bioavailability of approximately 40–60% due to first-pass hepatic metabolism, peak plasma concentrations at 2–3 hours, a volume of distribution (Vd) of approximately 3–4 L/kg reflecting extensive tissue distribution and lipophilicity, and a plasma half-life of 4–8 hours in healthy adults. Metabolism occurs primarily via CYP2D6 and CYP3A4 in the liver through N-demethylation, producing nordiphenhydramine and dinordiphenhydramine as metabolites. Because CYP2D6 is subject to genetic polymorphism and inhibition by common drugs including many antidepressants, plasma diphenhydramine concentrations can vary substantially between individuals, with CYP2D6 poor metabolizers achieving significantly higher plasma levels at standard doses. Renal excretion of unchanged drug is minimal; dose adjustment is required in severe hepatic impairment but not in renal failure.1
Hydroxyzine is a piperazine-class antihistamine with anxiolytic properties mediated through serotonin (5-HT) receptor antagonism and histamine H1 blockade, in addition to its anticholinergic activity. Its oral bioavailability exceeds 80%, peak concentrations occur at 2 hours, and its half-life of 20–25 hours in adults (extending to 40–50 hours in the elderly) makes it suitable for once-daily dosing but demands caution regarding drug accumulation. Hydroxyzine is extensively hepatically metabolized, with cetirizine as its principal active metabolite. This metabolic relationship is pharmacologically important: much of hydroxyzine's antihistamine effect at steady state is attributable to cetirizine accumulation, linking the two generations pharmacokinetically. The anxiolytic application of hydroxyzine at doses of 25–50 mg is supported by controlled trial data and represents a non-benzodiazepine alternative for short-term anxiety management in selected patients.3
Chlorpheniramine is an alkylamine-class antihistamine with relatively lower sedative and anticholinergic burden than diphenhydramine, making it one of the more tolerable first-generation agents. Its half-life of 12–24 hours allows twice-daily or once-daily dosing in adults. Hepatic metabolism via CYP2D6 and CYP3A4 produces desmethylchlorpheniramine as the active metabolite. Meclizine, a piperazine-class agent, is used almost exclusively for vestibular indications: motion sickness prophylaxis and the symptomatic management of vertigo, particularly benign paroxysmal positional vertigo (BPPV) and labyrinthine disorders. Its long half-life of approximately 6 hours (with duration of action extending to 12–24 hours in some patients) and relatively lower anticholinergic burden compared to promethazine make it preferable for these indications in most adult outpatients. Meclizine is poorly bioavailable by the oral route (approximately 25%) and undergoes hepatic metabolism without well-characterized active metabolites.1
Diphenhydramine is listed in the American Geriatrics Society Beers Criteria as a potentially inappropriate medication for older adults due to its high anticholinergic burden, sedative properties, and association with falls, delirium, and cognitive impairment. The pharmacokinetic basis is compounded in this population: reduced hepatic CYP2D6 activity with aging increases plasma concentrations, reduced renal clearance of metabolites prolongs effect, and age-related reductions in cholinergic neurotransmission amplify sensitivity to anticholinergic blockade. Clinicians should avoid recommending OTC diphenhydramine sleep aids to patients over 65 and should substitute with sedating antihistamines of lower anticholinergic burden (hydroxyzine at lower doses) or non-pharmacological approaches where feasible.
Second-generation H1 antihistamines, introduced from the 1980s onward, achieve selective peripheral H1 blockade with minimal CNS entry through a combination of reduced lipophilicity and active efflux by P-glycoprotein (P-gp) at the blood-brain barrier. Their freedom from anticholinergic and significant sedative effects has made them the standard of care for chronic allergic conditions, though individual agents within the class differ meaningfully in their ADME profiles, sedation potential, and interaction risks.
The primary mechanism limiting CNS penetration of second-generation antihistamines is efflux by P-glycoprotein (P-gp), encoded by the ABCB1 gene, which is expressed at high density on the luminal surface of brain endothelial cells. P-gp recognizes many lipophilic drug substrates and actively transports them back into the bloodstream, maintaining low brain interstitial concentrations even for compounds that have passively diffused across the endothelial lipid bilayer. Cetirizine, loratadine, fexofenadine, and their active metabolites are all P-gp substrates; the relative CNS exclusion efficiency differs among agents, which explains why cetirizine produces measurably more sedation than fexofenadine despite both being classified as non-sedating. In animal knockout models lacking functional P-gp, second-generation antihistamines produce substantial CNS H1 occupancy and behavioral sedation, confirming that P-gp efflux, not reduced lipophilicity alone, accounts for their peripheral selectivity.4
Loratadine is a tricyclic piperidine antihistamine with negligible anticholinergic activity and very low sedation at standard doses in most patients. It is rapidly absorbed orally, reaches peak plasma concentration at approximately 1–1.5 hours, and undergoes extensive first-pass hepatic metabolism to its active metabolite desloratadine via CYP3A4 and CYP2D6. Loratadine itself has a half-life of approximately 8 hours, while desloratadine has a longer half-life of approximately 27 hours, making the parent-to-metabolite ratio important for once-daily dosing coverage. Desloratadine is marketed as a separate agent with the advantage of bypassing the CYP-dependent first-pass step, potentially offering more predictable plasma levels than loratadine in patients receiving CYP inhibitors. Both are highly protein-bound (97–99%) and are not removed by dialysis. Dose adjustment is recommended in severe hepatic impairment; renal impairment does not require dose adjustment for loratadine but does for desloratadine (which is partially renally cleared).5
Cetirizine is the R-enantiomer metabolite of hydroxyzine (the racemic mixture) and is among the most extensively studied antihistamines in controlled trials. It has high oral bioavailability (greater than 70%), peak concentrations at 1 hour, a half-life of 8–9 hours, and is primarily renally eliminated as unchanged drug (approximately 70% of the dose), with minimal hepatic metabolism. This renal-dominant clearance makes cetirizine one of the antihistamines most sensitive to renal impairment: dose reduction to 5 mg daily is required when creatinine clearance (CrCl) falls below 31 mL/min, and caution is appropriate even at moderate impairment. Cetirizine produces more sedation than other second-generation agents in approximately 10–15% of recipients, an effect attributed to its relatively less efficient P-gp efflux at the BBB compared to fexofenadine. Protein binding is approximately 93%, volume of distribution 0.56 L/kg, reflecting lower tissue penetration than first-generation agents.5
Fexofenadine is the active carboxylate metabolite of terfenadine, an agent withdrawn from the market due to QT-prolonging cardiac arrhythmias. Fexofenadine itself lacks cardiac toxicity because it does not accumulate to the concentrations required for hERG potassium channel blockade. It has an oral bioavailability of approximately 30–40%, peak concentrations at 1–3 hours, and a half-life of 14–15 hours allowing once-daily dosing. Fexofenadine is primarily eliminated unchanged in feces (via biliary excretion) and urine, with minimal hepatic metabolism. It is one of the most CNS-sparing of all second-generation agents, an effect attributed to its very efficient P-gp-mediated efflux from the brain and its zwitterionic character at physiological pH, which limits passive membrane permeability. A unique and clinically important property of fexofenadine is its susceptibility to inhibition by the organic anion transporting polypeptide (OATP1A2) transporter in the gut: grapefruit juice, apple juice, and orange juice contain compounds that inhibit OATP1A2 and reduce fexofenadine bioavailability by up to 36%, a food-drug interaction discussed further in Section 4.5
Levocetirizine is the pharmacologically active R-enantiomer of cetirizine (the racemate) and offers the same H1 selectivity at half the dose (5 mg vs 10 mg). Its half-life of approximately 8 hours and predominantly renal elimination (approximately 85% of the dose excreted unchanged) closely parallel cetirizine pharmacokinetics, and dose adjustment in renal impairment follows the same creatinine clearance thresholds. Clinical trials comparing levocetirizine to cetirizine have shown comparable antihistamine efficacy and a modestly lower incidence of sedation, attributed to the elimination of the S-enantiomer component present in the racemate. Bilastine is a newer second-generation agent with very high H1 receptor selectivity, negligible anticholinergic activity, and a half-life of approximately 14 hours. Like fexofenadine, its absorption is significantly reduced by fruit juices via OATP inhibition; it should be taken on an empty stomach. Bilastine is not metabolized hepatically and is excreted predominantly unchanged, making it an attractive option in patients with hepatic impairment.5
Both cetirizine and fexofenadine are second-generation H1 antihistamines and P-glycoprotein (P-gp) substrates, but their CNS H1 occupancy differs substantially. Positron emission tomography (PET) studies measuring brain H1 receptor occupancy confirm that fexofenadine achieves essentially zero CNS occupancy at therapeutic doses, while cetirizine produces approximately 30% occupancy. The difference is attributable to: (1) more efficient P-gp efflux of fexofenadine, supported by its zwitterionic character reducing passive entry before efflux is even needed; and (2) cetirizine's relatively higher passive membrane permeability. For patients who experience sedation on cetirizine, switching to fexofenadine or levocetirizine at the 5 mg dose is a rational clinical maneuver. Patients who drive professionally or operate heavy machinery should be counseled that even low rates of sedation with cetirizine can be clinically relevant.
The elimination pathways of H1 antihistamines divide them into two broad pharmacokinetic categories: hepatically cleared agents requiring caution in liver failure but not renal failure, and renally cleared agents requiring dose reduction when creatinine clearance falls. This distinction is essential for safe antihistamine prescribing in patients with chronic kidney disease (CKD), cirrhosis, or combined organ dysfunction, populations who frequently require antihistamines for pruritus management.
Hepatic clearance dominates for loratadine, desloratadine (partially), diphenhydramine, hydroxyzine, chlorpheniramine, promethazine, and meclizine. The practical implication is that these agents can be used without dose adjustment in mild-to-moderate renal impairment (CrCl greater than 30 mL/min) but require dose reduction or avoidance in severe hepatic dysfunction (Child-Pugh class C cirrhosis), where CYP enzyme capacity is substantially reduced and protein binding may also be impaired due to hypoalbuminemia. In hepatic failure, both free drug fraction and half-life increase simultaneously, producing unpredictably elevated plasma concentrations. For first-generation agents with narrow therapeutic windows relative to their CNS adverse effects, this creates significant sedation and anticholinergic toxicity risk that is underappreciated clinically.1
Renal clearance dominates for cetirizine and levocetirizine, which are each excreted approximately 70–85% unchanged by the kidney via glomerular filtration and active tubular secretion. Fexofenadine has mixed elimination with roughly equal contributions from biliary and renal routes, and while modest dose reduction may be considered in severe renal failure, fexofenadine is generally better tolerated than cetirizine in patients with CKD because its bioavailability is lower and its CNS effect is negligible even if plasma levels rise. Cetirizine accumulation in renal failure warrants dose reduction: the standard recommendation is 5 mg once daily when CrCl is 11–31 mL/min, and 5 mg every other day in end-stage renal disease (ESRD). Patients on hemodialysis do not receive meaningful drug removal via dialysis due to cetirizine's high protein binding (93%), so dose intervals must be extended rather than relying on dialytic clearance.1
Half-life data determine dosing interval and the time to steady state, which equals approximately five half-lives regardless of the specific agent. For antihistamines used on an as-needed basis, half-life determines duration of symptom relief: diphenhydramine's 4–8-hour half-life necessitates every-6-hour dosing for sustained coverage, while fexofenadine's 14–15-hour half-life and once-daily dosing align conveniently. In the context of allergic rhinitis, once-daily dosing with a long-acting agent is associated with superior adherence compared to multiple-daily dosing schedules, and this adherence difference translates to meaningful differences in real-world symptom control. The concept of tachyphylaxis, a progressive reduction in antihistamine effect with continued use, was historically raised for H1 antihistamines but is not supported by consistent evidence; apparent loss of effect more often reflects inadequate dosing frequency or disease severity progression.6
Protein binding is high for essentially all H1 antihistamines (generally 80–99%), with loratadine and desloratadine at the upper end of this range. High protein binding has two clinical implications: first, it limits the volume of distribution and thereby reduces CNS penetration for agents that are also poor P-gp substrates; second, it means that hypoalbuminemia (from liver disease, nephrotic syndrome, malnutrition, or critical illness) increases the free drug fraction and amplifies pharmacological effects at any given total plasma concentration. Drug displacement interactions, where one highly protein-bound drug displaces another from albumin, are theoretically possible but rarely produce clinically meaningful changes in free drug levels because displaced drug rapidly redistributes into tissues. The exception occurs when both elimination capacity and albumin binding are impaired simultaneously, as in decompensated liver failure, where free drug elevation and prolonged half-life compound each other.1
Diphenhydramine: t½ 4–8 h; hepatic (CYP2D6/3A4); high anticholinergic; dose adjust in liver failure; no adjustment in renal failure.
Hydroxyzine: t½ 20–25 h (longer in elderly); hepatic; active metabolite cetirizine; dose adjust in liver failure and elderly; caution in renal failure due to metabolite accumulation.
Chlorpheniramine: t½ 12–24 h; hepatic (CYP2D6/3A4); moderate sedation; dose adjust in liver failure.
Loratadine: t½ 8 h (desloratadine 27 h); hepatic (CYP3A4/2D6); non-sedating; dose adjust in liver failure; no adjustment in renal failure.
Cetirizine: t½ 8–9 h; renal (70% unchanged); low sedation (outlier); dose reduce to 5 mg/day when CrCl <31 mL/min; no adjustment in liver failure.
Fexofenadine: t½ 14–15 h; mixed biliary/renal; negligible CNS; minimal dose adjustment in organ failure; OATP1A2 food interaction.
Levocetirizine: t½ 8 h; renal (85% unchanged); dose reduce in renal impairment as for cetirizine.
Bilastine: t½ 14 h; no hepatic metabolism; excreted unchanged; OATP interaction; take on empty stomach.
H1 antihistamine drug interactions occur through two distinct mechanisms: pharmacokinetic interactions that alter plasma concentrations by affecting metabolic enzymes or drug transporters, and pharmacodynamic interactions that amplify or antagonize clinical effects without changing plasma levels. Both categories are clinically important, and distinguishing them guides management strategies that range from dose adjustment to contraindication.
First-generation H1 antihistamines metabolized by CYP3A4 and CYP2D6 are subject to clinically significant pharmacokinetic interactions with CYP inhibitors. CYP3A4 inhibitors including azole antifungals (ketoconazole, itraconazole, fluconazole), macrolide antibiotics (erythromycin, clarithromycin), ritonavir and other HIV protease inhibitors, and grapefruit juice can substantially increase plasma concentrations of diphenhydramine, hydroxyzine, loratadine, and promethazine. For loratadine, which is a CYP3A4 substrate, co-administration with ketoconazole increases loratadine plasma area under the curve (AUC) by approximately 300%; because loratadine lacks cardiac toxicity at elevated concentrations, this interaction is pharmacokinetically meaningful but not dangerous in the same way the terfenadine-ketoconazole interaction was. CYP2D6 inhibitors, including paroxetine, fluoxetine, bupropion, and quinidine, reduce diphenhydramine clearance and can produce unexpectedly high plasma concentrations and anticholinergic toxicity at doses that are well-tolerated in the absence of the inhibitor.7
The fexofenadine-fruit juice interaction operates through a different mechanism: inhibition of the intestinal uptake transporter OATP1A2 (organic anion transporting polypeptide 1A2) rather than CYP enzyme inhibition. OATP1A2 is expressed on the luminal surface of intestinal epithelial cells and facilitates absorption of numerous drug substrates. Grapefruit juice, apple juice, and orange juice contain naringin, hesperidin, and related flavonoids that inhibit OATP1A2 at concentrations achieved with normal beverage consumption. When fexofenadine is taken with these juices, intestinal absorption is reduced by approximately 36%, lowering peak plasma concentrations and potentially compromising antihistamine efficacy. The practical recommendation is that fexofenadine should be taken with water rather than fruit juice, and the interaction window extends for approximately 4 hours after juice consumption. This interaction is a high-yield clinical detail because it is counterintuitive (juice reducing absorption rather than increasing it), mechanistically distinct from CYP interactions, and involves an extremely common food pairing.8
Pharmacodynamic interactions between sedating H1 antihistamines and other CNS depressants represent the most clinically consequential interaction category for first-generation agents. Alcohol, benzodiazepines, opioids, barbiturates, and non-benzodiazepine hypnotics all produce additive or supra-additive CNS depression when combined with sedating antihistamines, increasing the risk of excessive sedation, psychomotor impairment, respiratory depression, and in severe cases respiratory arrest. This interaction is particularly dangerous because diphenhydramine and similar agents are widely available OTC and are not systematically reviewed during medication reconciliation in many healthcare settings. Patients taking prescription opioids for pain management who self-medicate for insomnia or allergy with OTC diphenhydramine represent a high-risk combination that is underappreciated in clinical practice. The anticholinergic burden of first-generation agents is also additive with other anticholinergic medications, including tricyclic antidepressants (TCAs), bladder antimuscarinics (oxybutynin, tolterodine), first-generation antipsychotics, and antiparkinson agents with anticholinergic activity; the combined anticholinergic load can precipitate urinary retention, ileus, acute angle-closure glaucoma, and delirium in vulnerable patients.2
Second-generation H1 antihistamines have substantially fewer pharmacodynamic drug interactions due to their absence of anticholinergic activity and negligible CNS penetration. The interaction risk that remained relevant for second-generation agents historically was the QT prolongation seen with terfenadine and astemizole when combined with CYP3A4 inhibitors; both agents have been withdrawn from the US market. Current second-generation agents including cetirizine, fexofenadine, loratadine, and levocetirizine do not prolong QT at therapeutic plasma concentrations, and their combination with CYP inhibitors does not produce cardiac risk even when plasma levels are elevated. Nonetheless, the pharmacokinetic interactions affecting loratadine and cetirizine concentrations warrant attention in patients on multiple medications, and clinicians should review the full medication list when an antihistamine is added to a complex polypharmacy regimen.7
Terfenadine was withdrawn from the US market in 1997 after it was established that CYP3A4 inhibition by ketoconazole, erythromycin, and grapefruit juice elevated terfenadine plasma concentrations sufficiently to block hERG (human ether-a-go-go-related gene) potassium channels in cardiac myocytes, prolonging the QT interval and triggering fatal torsades de pointes arrhythmias. This interaction drove the development of fexofenadine, terfenadine's active metabolite, which lacks hERG affinity at therapeutic concentrations. Astemizole was withdrawn for the same mechanism. The terfenadine case became the paradigm example for drug-drug interaction-mediated cardiac toxicity and directly influenced the FDA's requirement for thorough QT studies (ICH E14 guidance) as part of new drug approval packages for all non-cardiac drugs.11
H1 antihistamine selection requires integrating pharmacokinetic, pharmacodynamic, and patient-specific considerations simultaneously. The choice of agent is rarely clinically neutral: first-generation agents offer CNS activity that is therapeutically valuable in certain contexts but hazardous in others, while second-generation agents provide superior safety and tolerability for most chronic allergic indications without the trade-off of sedation or anticholinergic toxicity.
Pregnancy pharmacology for H1 antihistamines requires careful evidence appraisal. Chlorpheniramine and diphenhydramine have the longest safety records in pregnancy and are the agents most commonly recommended in the first trimester when antihistamine use cannot be avoided; epidemiological data are reassuring for major malformations, though no antihistamine is definitively established as safe in the first trimester. Loratadine and cetirizine have been extensively studied in pregnancy registries and postmarketing databases and have not been associated with increased malformation rates in large observational studies; they are generally considered acceptable options in the second and third trimesters. Fexofenadine has more limited pregnancy data. The antiemetic applications of promethazine and doxylamine (in combination with pyridoxine as Diclegis/Bonjesta) in pregnancy-related nausea and vomiting are distinct indications with specific evidence bases; doxylamine-pyridoxine is the only FDA-approved treatment for nausea and vomiting of pregnancy in the United States. All H1 antihistamines cross the placenta, and all except those with extensive first-pass metabolism are detectable in breast milk; the clinical significance for nursing infants depends on the specific agent's CNS activity and infant age.6
Pediatric antihistamine pharmacology requires recognizing that children metabolize many drugs more rapidly than adults due to higher hepatic CYP enzyme activity relative to body weight, resulting in shorter half-lives and potentially requiring weight-adjusted dosing at the higher end of recommended ranges for adequate effect duration. First-generation agents including diphenhydramine and promethazine produce paradoxical excitation in a subset of young children rather than sedation, a phenomenon attributed to incomplete CNS inhibitory system maturation; this reaction, characterized by restlessness, insomnia, and hyperactivity, is recognized but unpredictable in individual patients. Promethazine carries an FDA black box warning against use in children under two years due to the risk of potentially fatal respiratory depression. Second-generation agents including loratadine, cetirizine, and fexofenadine are approved for children as young as two years of age for allergic rhinitis and urticaria and are preferred for outpatient pediatric allergy management. OTC formulations in age-appropriate weight-based doses have established safety records in this population.2
The clinical applications of H1 antihistamines span several therapeutic domains. In allergic rhinitis, second-generation oral antihistamines are effective for sneezing, rhinorrhea, nasal and ocular pruritus, and conjunctival injection but are less effective for nasal congestion than intranasal corticosteroids; guidelines recommend intranasal corticosteroids as first-line for persistent allergic rhinitis with antihistamines as adjunctive therapy. In acute urticaria, high-dose second-generation antihistamines are the mainstay of treatment; the current European Academy of Allergology and Clinical Immunology (EAACI) guideline recommends up-dosing (2–4 times the standard dose) of non-sedating antihistamines before considering alternative agents in chronic spontaneous urticaria (CSU) refractory to standard dosing.10 In anaphylaxis, antihistamines are adjunctive only, and epinephrine remains the sole primary intervention. In motion sickness, first-generation agents (particularly meclizine, dimenhydrinate, and promethazine) are superior to second-generation agents because vestibular suppression requires CNS H1 blockade; second-generation agents are essentially ineffective for this indication.6
The use of H1 antihistamines in chronic pruritus associated with atopic dermatitis, liver disease, and chronic kidney disease deserves specific comment. In atopic dermatitis, first-generation sedating antihistamines are sometimes used at bedtime to reduce nocturnal pruritus and improve sleep quality, but they do not address the underlying epidermal barrier dysfunction and Th2-driven inflammation; guidelines do not recommend them as regular therapy but acknowledge their role in sleep disturbance. Second-generation antihistamines have limited antipruritic efficacy in atopic dermatitis beyond placebo, which is consistent with the H4 receptor hypothesis that pruritus in this condition has a histamine-H4 component not addressed by H1 blockade alone. In cholestatic pruritus, antihistamines are generally ineffective; the preferred agents are bile acid sequestrants (cholestyramine), rifampicin, and naltrexone. In uremic pruritus associated with CKD, antihistamines show modest benefit at best; gabapentin and pregabalin have more consistent evidence in this indication and are now first-line in many guidelines.9
The EAACI/GA2LEN/EDF/WAO guideline for urticaria recommends a stepwise approach in which the dose of a non-sedating second-generation antihistamine is increased up to four times the standard dose before escalating to omalizumab (anti-IgE biologic). The pharmacological rationale is that H1 receptor occupancy increases with dose in a concentration-dependent manner, and standard doses may not achieve sufficient occupancy for complete symptom control in patients with high urticarial activity. Cetirizine, levocetirizine, fexofenadine, loratadine, and bilastine have all been studied at two to four times standard dose in clinical trials and found to be effective without alarming safety signals. Sedation may emerge at higher doses of cetirizine and levocetirizine at this dose escalation, which can be mitigated by dividing the dose or switching to fexofenadine or bilastine.10
Allergic rhinitis, chronic urticaria, conjunctivitis (outpatient, ongoing): Second-generation agent (loratadine, cetirizine, fexofenadine, levocetirizine, or bilastine). Avoid first-generation agents for daily chronic use.
Motion sickness: First-generation agent required (meclizine preferred for tolerability; promethazine for more refractory cases). Second-generation agents are ineffective.
Acute sedation or preoperative anxiolysis: Hydroxyzine 25–50 mg orally. Diphenhydramine is an alternative.
Nausea and vomiting of pregnancy: Doxylamine-pyridoxine (FDA-approved combination). Promethazine is an alternative for refractory cases.
Renal impairment (CrCl <30 mL/min): Avoid cetirizine and levocetirizine at standard doses or reduce dose; loratadine or fexofenadine preferred.
Hepatic impairment: Cetirizine, fexofenadine, or bilastine preferred (minimal hepatic metabolism); reduce loratadine dose interval.
Elderly patients: Avoid all first-generation agents (Beers Criteria). Use lowest effective dose of a second-generation agent.
Patients on opioids: Avoid first-generation agents; use second-generation agents if antihistamine is needed.
Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(6):1139–1150.
doi:10.1016/j.jaci.2011.09.005Church MK, Maurer M, Simons FE, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65(4):459–466.
doi:10.1111/j.1398-9995.2009.02325.xGuaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010;(12):CD006815.
doi:10.1002/14651858.CD006815.pub2Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003;31(3):312–318.
doi:10.1124/dmd.31.3.312Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet. 2008;47(4):217–230.
doi:10.2165/00003088-200847040-00001Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004;351(21):2203–2217.
doi:10.1056/NEJMra033121Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy. 1999;29(Suppl 3):116–124.
doi:10.1046/j.1365-2222.1999.0290s3116.xDresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71(1):11–20.
doi:10.1067/mcp.2002.121152Eusebio-Alpapara KMV, Castillo RL, Dofitas BL. Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. Int J Dermatol. 2020;59(4):412–422.
doi:10.1111/ijd.14708Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414.
doi:10.1111/all.13397Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32(4):489–498.
doi:10.1046/j.0954-7894.2002.01314.x